Journal Article

Skin toxicities associated with tumor treating fields: case based review

Lukas, Rimas V., Villano, John L., Wong, Eric T., Ratermann, Kelley L.

2017

Overview

The novel anti-mitotic based tumor treating fields (TTFields) is FDA approved for recurrent glioblastoma. Recently the phase III upfront trial combining the Novo TTF-100A device, called Optune, with temozolomide following concurrent radiation therapy and chemotherapy, demonstrated improvement in survival. Wider use of this novel therapy is expected. The most common adverse event is dermatologic, which dominates compared to the next most frequently observed adverse event of headaches, the incidence of which was even in both arms in the phase III registration trial for recurrent glioblastoma. Our case review outlines the presentation, treatment, and outcome of representative patients using TTFields. In summary, preventative strategies to inform and educate patients and operators can prevent many of these dermatological events. Skin toxicity in the setting of concurrent use of TTFields with other therapies such as bevacizumab is an unknown and will need to be closely followed.

• Publisher: Springer US,Springer Nature B.V
• Subject: Bevacizumab / Brain cancer / Chemotherapy / Clinical Study / Glioblastoma / Headache / Medicine / Medicine & Public Health / Monoclonal antibodies / Neurology / Oncology / Skin / Targeted cancer therapy / Temozolomide / Toxicity